Phase II Study of Postoperative Carbon Ion Radiotherapy Combined with Platinum-Based Chemotherapy for Advanced Thymic Epithelial Tumors After Surgery with Residual Tumor

What this Trial Is About

Researchers are evaluating the use of carbon ion radiotherapy combined with platinum-based chemotherapy in patients who have locally advanced or advanced thymic epithelial malignant tumors with visible residual tumor after surgery R2 resection. This phase II clinical study aims to observe the effectiveness and side effects of this treatment approach. The main focus is on progression-free survival and treatment-related toxicities, with additional measures including local relapse-free survival, overall survival, and cause-specific survival. Participants will receive carbon ion radiotherapy totaling 72 GyE, delivered in 18 fractions. Alongside this, patients will undergo at least four cycles of platinum-based chemotherapy regimens, which may include combinations such as etoposide with cisplatin, paclitaxel with cisplatin, or docetaxel with various platinum agents. The treatment regimen is carefully structured to combine radiation and chemotherapy for thorough management of thymus cancer. During the study, patients will be monitored regularly for disease progression and any adverse effects from treatment. Follow-up assessments will include clinical evaluations every 3 to 4 months for the first two years, then every 6 months from years 3 to 5, and annually thereafter, up to 100 months. Researchers will track survival rates and tumor progression to understand long-term outcomes. The total participation duration may extend up to several years due to extended monitoring.

Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor